Abstract
Gold –based nanoparticles are utilized for cancer therapeutics as a system for drug delivery, or as a mediator for thermal therapy, whether ablation or hyperthermia. This review discusses how the design of the physicochemical properties of the different types of gold-based nanoparticles affects their treatment efficacy. The basic principles and mechanism at which it mediates heating and delivers drugs efficiently in vivo is also summarized. We will also review the in vivo preclinical data on the biodistribution, intratumoral distribution, cell internalization, and its associated toxicity. Lastly, an updated list of the clinical trials based on nanoparticles and future perspectives are provided.
Keywords: Gold nanoparticles, biodistribution, toxicity, laser ablation, drug delivery, hyperthermia.
Current Pharmaceutical Design
Title:Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
Volume: 21 Issue: 29
Author(s): Jun Zhao, Patrick Lee, Michael J. Wallace and Marites P. Melancon
Affiliation:
Keywords: Gold nanoparticles, biodistribution, toxicity, laser ablation, drug delivery, hyperthermia.
Abstract: Gold –based nanoparticles are utilized for cancer therapeutics as a system for drug delivery, or as a mediator for thermal therapy, whether ablation or hyperthermia. This review discusses how the design of the physicochemical properties of the different types of gold-based nanoparticles affects their treatment efficacy. The basic principles and mechanism at which it mediates heating and delivers drugs efficiently in vivo is also summarized. We will also review the in vivo preclinical data on the biodistribution, intratumoral distribution, cell internalization, and its associated toxicity. Lastly, an updated list of the clinical trials based on nanoparticles and future perspectives are provided.
Export Options
About this article
Cite this article as:
Zhao Jun, Lee Patrick, Wallace J. Michael and Melancon P. Marites, Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity, Current Pharmaceutical Design 2015; 21 (29) . https://dx.doi.org/10.2174/1381612821666150901103032
DOI https://dx.doi.org/10.2174/1381612821666150901103032 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Role of ABC Transporters in the Chemoresistance of Human Gliomas
Current Cancer Drug Targets The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets Fabrication of Poly Hydroxybutyrate-Polyethylene Glycol-Folic Acid Nanoparticles Loaded by Paclitaxel
Current Drug Delivery Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Terpenes with Antitumor Activity: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Effect of PUFAs Oral Administration on the Amount of Apoptotic Caspases Enzymes in Gastric Cancer Patients Undergoing Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Current Medicinal Chemistry Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Oncolytic Viruses Driven by Tumor-Specific Promoters
Current Cancer Drug Targets Nanosponge Carriers- An Archetype Swing in Cancer Therapy: A Comprehensive Review
Current Drug Targets Dietary Assumption of Plant Polyphenols and Prevention of Allergy
Current Pharmaceutical Design PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Current Medicinal Chemistry Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued)